NasdaqCM - Nasdaq Real Time Price USD
Immunome, Inc. (IMNM)
8.48
-0.02
(-0.18%)
As of 9:49:48 AM EDT. Market Open.
Insider Purchases Last 6 Months
Shares | Transactions | |
---|---|---|
Purchases | 0 | 0 |
Sales | -- | 0 |
Net Shares Purchased (Sold) | 0 | 0 |
Total Insider Shares Held | 14.11M | -- |
% Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
Shares | |
---|---|
Net Shares Purchased (Sold) | -- |
% Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
Insider | Transaction | Type | Value | Date |
---|---|---|---|---|
HIGGINS JACK Officer | Conversion of Exercise of derivative security at price 1.35 per share. | Direct | 7,020 | Mar 27, 2025 |
SIEGALL CLAY B Chief Executive Officer | Purchase at price 7.29 per share. | Direct | 999,459 | Mar 26, 2025 |
BIENAIME JEAN-JACQUES Director | Purchase at price 7.78 per share. | Direct | 60,684 | Mar 25, 2025 |
BIENAIME JEAN-JACQUES Director | Purchase at price 8.21 per share. | Direct | 57,470 | Mar 24, 2025 |
TSAI PHILIP S. L. Chief Technology Officer | Purchase at price 8.42 per share. | Direct | 103,566 | Mar 24, 2025 |
SIEGALL CLAY B Chief Executive Officer | Purchase at price 11.03 per share. | Direct | 1,654,500 | Jan 31, 2025 |
SIEGALL CLAY B Chief Executive Officer | Purchase at price 9.54 - 9.78 per share. | Direct | 962,181 | Nov 22, 2024 |
LECHLEIDER ROBERT M.D. Officer | Purchase at price 9.48 per share. | Direct | 149,800 | Nov 21, 2024 |
TSAI PHILIP S. L. Chief Technology Officer | Purchase at price 9.43 per share. | Direct | 198,030 | Nov 21, 2024 |
ROSETT MAX Chief Financial Officer | Conversion of Exercise of derivative security at price 1.05 per share. | Direct | 44,100 | Sep 19, 2024 |
ROSETT MAX Chief Financial Officer | Sale at price 16.01 per share. | Direct | 230,224 | Sep 19, 2024 |
HIGGINS JACK Officer | Stock Gift at price 0.00 per share. | Direct | 0 | Aug 19, 2024 |
BIENAIME JEAN-JACQUES Director | Purchase at price 13.94 per share. | Direct | 97,608 | Aug 16, 2024 |
HIGGINS JACK Officer | Conversion of Exercise of derivative security at price 1.35 per share. | Direct | 26,357 | Aug 15, 2024 |
HIGGINS JACK Officer | Sale at price 13.92 per share. | Direct | 49,072 | Aug 15, 2024 |
BIENAIME JEAN-JACQUES Director | Purchase at price 13.57 per share. | Direct | 27,140 | May 21, 2024 |
SIEGALL CLAY B Chief Executive Officer | Purchase at price 13.78 - 13.91 per share. | Direct | 1,388,072 | May 21, 2024 |
SIEGALL CLAY B Chief Executive Officer | Purchase at price 8.20 per share. | Direct | 1,387,473 | Oct 2, 2023 |
TURNER BRUCE C Officer | Purchase at price 8.20 per share. | Direct | 346,860 | Oct 2, 2023 |
PRENDERGAST FRANKLYN G Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Oct 2, 2023 |
RAPP MICHAEL Director | Stock Award(Grant) at price 8.20 per share. | Direct | 2,081,209 | Oct 2, 2023 |
Related Tickers
SWTX SpringWorks Therapeutics, Inc.
40.87
-0.82%
IMNN Imunon, Inc.
0.8766
-2.38%
COGT Cogent Biosciences, Inc.
4.4700
0.00%
JANX Janux Therapeutics, Inc.
31.39
-0.73%
TRML Tourmaline Bio, Inc.
17.39
-2.41%
KURA Kura Oncology, Inc.
6.42
+0.78%
APLS Apellis Pharmaceuticals, Inc.
17.67
+1.03%
AKRO Akero Therapeutics, Inc.
39.79
+0.44%
IMVT Immunovant, Inc.
14.61
+1.11%
BCYC Bicycle Therapeutics plc
8.49
-2.06%